Bicara Therapeutics CMO David Raben Exercises Options and Sells Shares

On April 27, 2026, David Raben, Chief Medical Officer of Bicara Therapeutics Inc. (BCAX), executed a complex stock transaction involving both option exercises and share sales. Raben exercised 5,500 stock options at an exercise price of $3.7898 per share, acquiring the underlying common shares. Simultaneously, he sold the same 5,500 shares at a weighted average price of $22.8782 per share, resulting in a significant profit. The transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025, indicating pre-planned trading activity. Following these transactions, Raben's direct holdings decreased to 55,286 common shares, while he retains 41,913 stock options. The option exercise was part of a vesting schedule with quarterly installments following August 8, 2023. The share sales occurred at prices ranging from $22.51 to $23.07, demonstrating substantial appreciation from the exercise price.